The IPO removes near-term financing risk and funds pipeline through 2029, but the stock will trade on clinical catalysts — watch for Phase 3 GT trial initiation in H2 2026 and data readouts for sutacimig (FVII deficiency) and HMB-002 (VWD) in late 2026/early 2027. No revenue or guidance to anchor valuation.
Price Chart
Executive Summary
Hemab Therapeutics reported a Q1 2026 net loss of $22.7M ($23.98/share), widening from a $15.3M loss ($16.18/share) in Q1 2025, driven by higher R&D and G&A expenses. The company completed a $346.7M IPO in May 2026, extending its cash runway into 2029, and received FDA Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia. As a pre-revenue clinical-stage biotech, the earnings report itself is routine, but the IPO proceeds and regulatory milestone are the key value drivers.
Key Financial Metrics
Key Facts
- Net loss of $22.7M in Q1 2026 vs $15.3M in Q1 2025, driven by R&D expenses of $19.5M (up from $14.1M) and G&A of $4.2M (up from $2.5M).
- Cash, cash equivalents, and marketable securities totaled $163.5M as of March 31, 2026; combined with $317.2M net IPO proceeds in May 2026, cash runway extends into 2029.
- Completed upsized IPO of 19.26M shares at $18.00/share, raising $346.7M in gross proceeds.
- FDA granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia in March 2026.
- Phase 3 pivotal trial for sutacimig in GT expected to initiate in H2 2026; Phase 2 data for Factor VII deficiency and Phase 1/2 data for HMB-002 expected in late 2026 or early 2027.
Financial Impact
Net loss widened by $7.4M YoY; IPO added $346.7M gross proceeds; cash runway extended into 2029.
Risk Factors
- Pre-revenue clinical-stage company with no approved products; valuation depends entirely on pipeline success.
- Phase 3 GT trial may fail to meet endpoints; regulatory path for Breakthrough Therapy designation is not guaranteed.
- Cash burn rate is increasing as programs advance; additional financing may be needed beyond 2029.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3299177 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $49.87 $44.50 | ▼ −10.77% | ▼ −9.71% | $30.36 (−39.12%) |
Jun 17, 2026 15w ago | Insider Buy | $29.24 $44.53 | ▲ +52.29% | ▲ +51.76% | $30.36 (+3.83%) |
May 21, 2026 19w ago | Press Release | $26.30 $31.83 | ▲ +21.03% | ▲ +20.69% | $30.36 (+15.44%) |
May 4, 2026 21w ago | 8-K | $25.00 $27.47 | ▲ +9.88% | ▲ +4.93% | $30.36 (+21.44%) |
Apr 30, 2026 22w ago | Press Release | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
Apr 30, 2026 22w ago | 3 | $34.00 $27.13 | ▼ −20.21% | ▼ −25.47% | $30.36 (−10.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access